Clinically Evaluated Parkinson’s Device Platform In Keiretsu Forum-MST ReStart Program to Accelerate Commercialization

Resonate Devices joins Keiretsu Forum-MST ReStart with two wearable vibration-therapy technologies, supported by IP, regulatory, and commercialization pathways.

PHILADELPHIA, PA, UNITED STATES, August 13, 2026 /EINPresswire.com/ — Resonate Devices, a medical device company developing wearable vibration therapies for people living with Parkinson’s disease and essential tremor, has joined the Keiretsu Forum-MST ReStart Program to prepare for commercial market entry and syndicate its upcoming financing round.

Resonate Devices is advancing two complementary, non-invasive technologies designed to address disruptive movement symptoms:
• RMBand: A wrist or upper-arm wearable engineered to reduce time spent experiencing hand and arm tremors.
• VibeForward: An ankle-worn device designed to improve speed, balance, and mobility for people affected by freezing of gait, a Parkinson’s symptom that temporarily prevents stepping forward.

The platform is supported by an issued U.S. patent, an additional provisional filing, and both technologies have been clinically evaluated; early data support continued product development.

The company is advancing product development and regulatory planning for both technologies, including targeted Class II submissions in 2027.

The Keiretsu ReStart Program provides structured governance, operational alignment, and capital syndication for high-potential technology companies. Through the program, Keiretsu Forum-MST will work with Resonate leadership to prepare the company for capital formation and establish clear execution milestones toward commercialization and liquidity.

“Resonate Devices combines rigorous clinical data with a clear market need,” said Howard Lubert, President of Keiretsu Forum-MST. “Our focus is deploying targeted growth capital and executive oversight to take this platform through its FDA regulatory filings and directly into commercial deployment.”

The company’s leadership team includes Chief Executive Officer Kevin Tanguay and Chief Scientific Officer Dr. Ingrid Pretzer-Aboff. Christian Haller and Howard Lubert serve on the company’s Board of Directors.

“We have transitioned from years of research and clinical evaluation into a company focused on regulatory execution and commercialization,” said Kevin Tanguay, CEO of Resonate Devices. “With near-term regulatory and commercialization milestones, including targeted 2027 Class II submissions, and with the support of Keiretsu’s investor network, we have the governance and are well positioned to deliver the capital structure required to bring these non-invasive devices to patients.”

According to data from the Parkinson’s Foundation, Parkinson’s disease affects more than 10 million people worldwide, with approximately 70% experiencing tremors and 80% suffering from gait disruption. Resonate’s targeted vibration therapy is designed to influence communication between peripheral limbs and the motor cortex, offering a non-pharmaceutical option to integrate into daily life alongside standard treatments.

“The clinical research behind these wearables spans more than a decade of development,” said Dr. Ingrid Pretzer-Aboff, Chief Scientific Officer. “Partnering with Keiretsu Forum-MST ensures we have the operational foundation to bring these clinical insights out of the laboratory and into the hands of clinicians and patients.”

For additional information, visit Resonate Devices at https://resonatedevices.com/

About Resonate Devices
Resonate Devices is developing wearable vibration-therapy technologies for people living with Parkinson’s disease and essential tremor. Its platform includes RMBand, a wrist or upper-arm device addressing tremor, and VibeForward, an ankle-worn device addressing freezing of gait. The company is led by an executive team with deep expertise in medical devices, neurology, product development, and venture execution. For more information, visit https://resonatedevices.com/

About Keiretsu Forum-MST
Keiretsu Forum-MST is an accredited investor community serving the Mid-Atlantic, Southeast, and Texas regions. The organization provides curated deal flow, structured screening, investor-led due diligence, governance participation, and cross-chapter syndication.
For more information, visit www.K4-MST.com.

Cynthia D Sutera
AMS Communications.net
+1 610-613-2773
email us here
Visit us on social media:
LinkedIn

Media gallery